<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360ee–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360ee–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360ee–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360ee_1"><akn:num>360ee–1</akn:num><akn:heading>FDA rare neurodegenerative disease grant program</akn:heading><akn:content><akn:p>§ 360ee–1. FDA rare neurodegenerative disease grant program
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—(1) to characterize such neurodegenerative diseases and their natural history;

(2) to identify molecular targets for such neurodegenerative diseases; and

(3) to increase efficiency and productivity of clinical development of therapies, including through—(A) the use of master protocols and adaptive and add-on clinical trial designs; and

(B) efforts to establish new or leverage existing clinical trial networks.


(Pub. L. 117–79, § 5, Dec. 23, 2021, 135 Stat. 1537.)

Editorial Notes
Codification
Section was enacted as part of the Accelerating Access to Critical Therapies for ALS Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.</akn:p></akn:content><akn:subsection eId="subsec_360ee_1_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1) to characterize such neurodegenerative diseases and their natural history;</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360ee_1_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) to identify molecular targets for such neurodegenerative diseases; and</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360ee_1_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3) to increase efficiency and productivity of clinical development of therapies, including through—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>